Obstructive sleep apnea and cardiovascular risk.

Area of Science:

• Cardiology
• Sleep Medicine
• Pulmonology

Background:

• Obstructive sleep apnea (OSA) involves recurrent upper airway collapse during sleep, leading to intermittent hypoxia.
• Intermittent hypoxia triggers sympathetic overactivation, endothelial dysfunction, hypercoagulation, and metabolic dysregulation.
• These mechanisms contribute to hypertension, metabolic syndrome, diabetes, and target organ damage, increasing cardiovascular morbidity and mortality.

Purpose of the Study:

• To review the cardiovascular implications of obstructive sleep apnea.
• To evaluate the efficacy of Continuous Positive Airway Pressure (CPAP) in managing OSA-related cardiovascular risks.
• To identify future research directions for optimizing OSA treatment in cardiovascular risk reduction.

Main Methods:

• Literature review of studies on obstructive sleep apnea pathophysiology and cardiovascular consequences.
• Analysis of clinical trial data on Continuous Positive Airway Pressure (CPAP) therapy for OSA.
• Synthesis of evidence regarding CPAP's impact on blood pressure and cardiovascular events.

Main Results:

• Continuous Positive Airway Pressure (CPAP) demonstrates mild benefits in reducing blood pressure, especially in resistant hypertension.
• CPAP treatment shows potential in reducing cardiovascular events for primary and secondary prevention.
• Treatment benefits are significant only in patients with high compliance (CPAP use ≥4 hours/night).

Conclusions:

• Obstructive sleep apnea is a significant contributor to cardiovascular risk through multiple pathophysiological pathways.
• Continuous Positive Airway Pressure (CPAP) is a key treatment for OSA, offering modest cardiovascular benefits.
• Future research should focus on identifying OSA patients who will most benefit from CPAP to mitigate cardiovascular risk.